In this respect, anti-human SIRPα antibodies have been developed for the treatment of HCC and assessed in a clinical trial (NCT02868255), being the objective of this trial to harvest samples from patients with HCC (inflammatory ascites, HCC resections and blood samples) to evaluate SIRP-CD47 expression and the effect of the anti-hSIRP Ab on various cellular types. Here, CD47 is linked to hepatocellular carcinoma.